A cross-sectional analysis from Yale School of Medicine estimates that approximately 5.8 million adolescents and 11.1 million young adults in the United States meet eligibility criteria for glucagon-like peptide-1 receptor agonists (GLP-1RAs), drugs approved to treat obesity and type 2 diabetes (T2D) in some pediatric populations.
This article was originally published on MedicalXpress.com
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
© 2025 SimplyWell.ca